Comparative molecular analysis of primary and recurrent oligodendroglioma that acquired imbalanced 1p/19q codeletion and TP53 mutation: a case report.
Acta Neurochir (Wien)
; 162(12): 3019-3024, 2020 12.
Article
em En
| MEDLINE
| ID: mdl-32785787
ABSTRACT
Oligodendroglioma is defined by IDH mutation and 1p/19q codeletion. Normal TP53 status is also its molecular feature. We report a case of oligodendroglioma that acquired imbalanced 1p/19q codeletion and TP53 mutation at recurrence after temozolomide therapy. The primary and recurrent tumors shared IDH1 and TERT promoter mutations. Although 1p/19q was codeleted in the primary tumor, it was imbalanced in the recurrent tumor harboring TP53 mutation. The copy-neutral loss of heterozygosity might have imbalanced the 1p/19q codeletion, while temozolomide therapy possibly caused the TP53 mutation. Such phenomena, although rare, should be noted during the clinical treatment of oligodendrogliomas.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Oligodendroglioma
/
Neoplasias Encefálicas
/
Proteína Supressora de Tumor p53
/
Isocitrato Desidrogenase
/
Mutação
Limite:
Adult
/
Female
/
Humans
Idioma:
En
Revista:
Acta Neurochir (Wien)
Ano de publicação:
2020
Tipo de documento:
Article
País de afiliação:
Japão